Open AccessCombination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma
Author(s) -
Shuhei Teranishi,
CHIHIRO SUGIMOTO,
HIROKAZU NAGAYAMA,
WATARU SEGAWA,
Atsushi Miyasaka,
SHUNTARO HIRO,
Chihiro Maeda,
Hironori Tamura,
Nobuyuki Masumoto,
YOSHINORI NAGAHARA,
Nobuyuki Hirama,
Nobuaki Kobayashi,
Masaki Yamamoto,
Makoto Kudo,
Takeshi Kaneko
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10102
Subject(s) - pembrolizumab , chemotherapy , medicine , adenocarcinoma , lung cancer , oncology , small cell carcinoma , cancer , immunotherapy
Pulmonary enteric adeno-carcinoma (PEAC) is a rare type of non-small cell lung cancer (NSCLC), for which no established standard treatment exists. Combination therapy with the anti-programmed cell death protein 1 antibody pembrolizumab and platinum-containing chemotherapy is the standard treatment for NSCLC patients, but its effectiveness in PEAC is uncertain.